Does the media refer more to VERA or ZVRA?

In the previous week, Vera Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Vera Therapeutics and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Vera Therapeutics' score of 0.88 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZVRA or KOD?

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 2 articles in the media. Zevra Therapeutics' average media sentiment score of 0.93 equaled Kodiak Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kodiak Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RARE or ZVRA?

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 5 mentions for Ultragenyx Pharmaceutical and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Ultragenyx Pharmaceutical's score of 0.79 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ADPT or ZVRA?

In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Adaptive Biotechnologies and 2 mentions for Zevra Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.42 beat Zevra Therapeutics' score of 0.93 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZLAB or ZVRA more profitable?

Zevra Therapeutics has a net margin of 101.58% compared to Zai Lab's net margin of -39.29%. Zevra Therapeutics' return on equity of 51.49% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -39.29% -24.32% -15.52% Zevra Therapeutics 101.58% 51.49% 28.86%

Does the media refer more to ZLAB or ZVRA?

In the previous week, Zai Lab had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 3 mentions for Zai Lab and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Zai Lab's score of 0.62 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zevra Therapeutics (ZVRA) Competitors

$10.87 -0.01 (-0.09%)

As of 12:27 PM Eastern

Compare

ZVRA vs. VERA, KOD, RARE, ADPT, and ZLAB

Should you buy Zevra Therapeutics stock or one of its competitors? MarketBeat compares Zevra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zevra Therapeutics include Vera Therapeutics (VERA), Kodiak Sciences (KOD), Ultragenyx Pharmaceutical (RARE), Adaptive Biotechnologies (ADPT), and Zai Lab (ZLAB). These companies are all part of the "pharmaceutical products" industry.

How does Zevra Therapeutics compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Vera Therapeutics had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Vera Therapeutics and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Vera Therapeutics' score of 0.88 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vera Therapeutics currently has a consensus target price of $78.00, indicating a potential upside of 154.15%. Zevra Therapeutics has a consensus target price of $23.33, indicating a potential upside of 114.66%. Given Vera Therapeutics' higher possible upside, research analysts plainly believe Vera Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Zevra Therapeutics has a net margin of 101.58% compared to Vera Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Zevra Therapeutics	101.58%	51.49%	28.86%

Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Zevra Therapeutics	$106.47M	6.04	$83.23M	$1.99	5.46

Summary

Zevra Therapeutics beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Kodiak Sciences?

Zevra Therapeutics (NASDAQ:ZVRA) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Zevra Therapeutics presently has a consensus price target of $23.33, suggesting a potential upside of 114.66%. Kodiak Sciences has a consensus price target of $42.14, suggesting a potential upside of 27.90%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Zevra Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Zevra Therapeutics and Zevra Therapeutics both had 2 articles in the media. Zevra Therapeutics' average media sentiment score of 0.93 equaled Kodiak Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kodiak Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.04	$83.23M	$1.99	5.46
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Zevra Therapeutics has a net margin of 101.58% compared to Kodiak Sciences' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Kodiak Sciences	N/A	-253.85%	-81.48%

Summary

Zevra Therapeutics beats Kodiak Sciences on 10 of the 13 factors compared between the two stocks.

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Ultragenyx Pharmaceutical had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 5 mentions for Ultragenyx Pharmaceutical and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Ultragenyx Pharmaceutical's score of 0.79 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	3.28	-$575M	-$6.11	N/A
Zevra Therapeutics	$106.47M	6.04	$83.23M	$1.99	5.46

Ultragenyx Pharmaceutical currently has a consensus target price of $59.56, suggesting a potential upside of 166.14%. Zevra Therapeutics has a consensus target price of $23.33, suggesting a potential upside of 114.66%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Ultragenyx Pharmaceutical has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has a net margin of 101.58% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Zevra Therapeutics' return on equity of 51.49% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Zevra Therapeutics	101.58%	51.49%	28.86%

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Zevra Therapeutics beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Zevra Therapeutics has a net margin of 101.58% compared to Adaptive Biotechnologies' net margin of -16.82%. Zevra Therapeutics' return on equity of 51.49% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Zevra Therapeutics	101.58%	51.49%	28.86%

Adaptive Biotechnologies currently has a consensus price target of $19.57, indicating a potential upside of 26.76%. Zevra Therapeutics has a consensus price target of $23.33, indicating a potential upside of 114.66%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zevra Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	8.92	-$59.50M	-$0.33	N/A
Zevra Therapeutics	$106.47M	6.04	$83.23M	$1.99	5.46

In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Adaptive Biotechnologies and 2 mentions for Zevra Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.42 beat Zevra Therapeutics' score of 0.93 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a beta of 2.15, suggesting that its stock price is 115% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

Zevra Therapeutics beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Zai Lab had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 3 mentions for Zai Lab and 2 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat Zai Lab's score of 0.62 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zevra Therapeutics has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	4.22	-$175.54M	-$1.62	N/A
Zevra Therapeutics	$106.47M	6.04	$83.23M	$1.99	5.46

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zai Lab currently has a consensus target price of $45.83, suggesting a potential upside of 167.56%. Zevra Therapeutics has a consensus target price of $23.33, suggesting a potential upside of 114.66%. Given Zai Lab's higher possible upside, research analysts plainly believe Zai Lab is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.63
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Zevra Therapeutics has a net margin of 101.58% compared to Zai Lab's net margin of -39.29%. Zevra Therapeutics' return on equity of 51.49% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-39.29%	-24.32%	-15.52%
Zevra Therapeutics	101.58%	51.49%	28.86%

Zai Lab has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Summary

Zevra Therapeutics beats Zai Lab on 11 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$642.63M	$2.90B	$6.26B	$12.44B
Dividend Yield	N/A	1.79%	2.69%	5.30%
P/E Ratio	5.46	17.66	22.35	24.23
Price / Sales	6.04	488.35	555.60	126.08
Price / Cash	12.15	56.38	42.31	57.88
Price / Book	3.95	3.84	9.82	6.73
Net Income	$83.23M	$75.85M	$3.56B	$336.97M
7 Day Performance	-0.73%	-2.13%	-1.16%	0.79%
1 Month Performance	7.94%	21.60%	3.85%	5.38%
1 Year Performance	22.55%	21.15%	27.33%	34.55%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.5247 of 5 stars	$10.87 -0.1%	$23.33 +114.7%	+25.6%	$642.63M	$106.47M	5.46	20
VERA Vera Therapeutics	3.3355 of 5 stars	$34.04 -0.9%	$79.00 +132.1%	-1.5%	$2.47B	N/A	N/A	40	News Coverage Analyst Forecast
KOD Kodiak Sciences	2.7237 of 5 stars	$36.23 -3.2%	$42.14 +16.3%	+822.8%	$2.34B	N/A	N/A	90
RARE Ultragenyx Pharmaceutical	2.8344 of 5 stars	$23.39 -1.3%	$59.88 +156.0%	-39.7%	$2.30B	$670M	N/A	1,371	Insider Trade
ADPT Adaptive Biotechnologies	3.4525 of 5 stars	$13.88 +0.1%	$19.57 +41.0%	+58.5%	$2.22B	$295.41M	N/A	790	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. VERA, KOD, RARE, ADPT, and ZLAB

How does Zevra Therapeutics compare to Vera Therapeutics?

Summary

How does Zevra Therapeutics compare to Kodiak Sciences?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Summary

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Summary

How does Zevra Therapeutics compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. VERA, KOD, RARE, ADPT, and ZLAB

How does Zevra Therapeutics compare to Vera Therapeutics?

Does the media refer more to VERA or ZVRA?

Do insiders & institutionals hold more shares of VERA or ZVRA?

Do analysts recommend VERA or ZVRA?

Is VERA or ZVRA more profitable?

Which has more risk & volatility, VERA or ZVRA?

Which has better valuation & earnings, VERA or ZVRA?

Summary

How does Zevra Therapeutics compare to Kodiak Sciences?

Do analysts prefer ZVRA or KOD?

Does the media refer more to ZVRA or KOD?

Do institutionals & insiders hold more shares of ZVRA or KOD?

Which has more risk and volatility, ZVRA or KOD?

Which has stronger valuation & earnings, ZVRA or KOD?

Is ZVRA or KOD more profitable?

Summary

How does Zevra Therapeutics compare to Ultragenyx Pharmaceutical?

Does the media refer more to RARE or ZVRA?

Which has better earnings and valuation, RARE or ZVRA?

Do analysts prefer RARE or ZVRA?

Which has more volatility and risk, RARE or ZVRA?

Is RARE or ZVRA more profitable?

Do institutionals and insiders hold more shares of RARE or ZVRA?

Summary

How does Zevra Therapeutics compare to Adaptive Biotechnologies?

Is ADPT or ZVRA more profitable?

Do analysts recommend ADPT or ZVRA?

Do insiders and institutionals hold more shares of ADPT or ZVRA?

Which has preferable valuation & earnings, ADPT or ZVRA?

Does the media prefer ADPT or ZVRA?

Which has more risk and volatility, ADPT or ZVRA?

Summary

How does Zevra Therapeutics compare to Zai Lab?

Does the media refer more to ZLAB or ZVRA?

Which has preferable earnings & valuation, ZLAB or ZVRA?

Do insiders & institutionals hold more shares of ZLAB or ZVRA?

Do analysts rate ZLAB or ZVRA?

Is ZLAB or ZVRA more profitable?

Which has more risk and volatility, ZLAB or ZVRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools